Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 11. Effects of oral labetalol in patients with both angina pectoris and hypertension: a preliminary experience
| Autor: | Joel A. Strom, William H. Frishman, Stanley Halprin, Marc Kirschner |
|---|---|
| Rok vydání: | 1980 |
| Předmět: |
medicine.medical_specialty
Clinical pharmacology Adrenergic receptor business.industry musculoskeletal neural and ocular physiology Treadmill testing medicine.disease Essential hypertension Placebo law.invention Angina law Internal medicine Anesthesia medicine Cardiology In patient cardiovascular diseases Cardiology and Cardiovascular Medicine Labetalol business circulatory and respiratory physiology medicine.drug |
| Zdroj: | American Heart Journal. 99:388-396 |
| ISSN: | 0002-8703 |
| DOI: | 10.1016/0002-8703(80)90354-3 |
| Popis: | The safety and efficacy of oral labetalol, an alpha-beta-adrenergic blocking drug, was assessed in six patients with both angina pectoris and essential hypertension. Patients received a placebo for 3 weeks which was followed by a 4 week titration of labetalol (100 to 400 mg. three times a day). The dose was then withdrawn over a 2 day period. With maximum doses of labetalol, exercise tolerance as measured by multistage treadmill testing increased significantly compared to placebo (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|